Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nazanin Pouya

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Computers & Chemical Engineering|April 23, 2026
Using Machine Learning to Design Effective Antimicrobial Dosing RegimensHimanshu Galgat, Nazanin Pouya, Vincent H Tam, et al.
Journal of Global Antimicrobial Resistance|July 12, 2024
In vitro evaluation of using ceftazidime/avibactam against carbapenem-resistant Acinetobacter baumanniiNazanin Pouya, James E Smith, Cole S Hudson, et al.
Computers & Chemical Engineering|January 9, 2025
Rapid Design of Combination Antimicrobial Therapy against <i>Acinetobacter baumannii</i>Brianna M Eales, James Smith, Nazanin Pouya, et al.
Antimicrobial Agents and Chemotherapy|September 22, 2025
Pharmacokinetics of sulbactam-durlobactam in patients with <i>Acinetobacter baumannii</i> ventriculitis: a report of two casesNazanin Pouya, Natalie A Finch, Alejandro Granillo, et al.
Pharmacotherapy|December 4, 2024
Pharmacokinetics of cefiderocol in a patient with carbapenem-resistant Acinetobacter baumannii ventriculitis: A case reportNatalie A Finch, Alejandro Granillo, Nazanin Pouya, et al.
International Journal of Antimicrobial Agents|May 9, 2024
Alternative iron-depleted media for cefiderocol susceptibility testingBrianna M Eales, James E Smith, Nazanin Pouya, et al.
Diagnostic Microbiology and Infectious Disease|July 12, 2025
Impact of iron limitation on in vitro and in vivo activity of ceftazidime against A. baumanniiBrianna M Eales, James E Smith, Nazanin Pouya, et al.
Antimicrobial Agents and Chemotherapy|July 8, 2025
Drug development studies supporting zileuton as a parenteral adjuvant to attenuate antibiotic-associated nephrotoxicityCole S Hudson, James E Smith, Linh T Vuong, et al.
The Journal of Infectious Diseases|May 15, 2026
Genomic and Clinical Features Associated with Reduced Susceptibility to Cefiderocol and Cross-resistance to β-lactam/β-lactamase Inhibitors in a Global Cohort of Pseudomonas aeruginosaStephanie L Egge, Donghoon Kang, Nazanin Pouya, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Computers & Chemical Engineering|April 23, 2026
Using Machine Learning to Design Effective Antimicrobial Dosing RegimensHimanshu Galgat, Nazanin Pouya, Vincent H Tam, et al.
Journal of Global Antimicrobial Resistance|July 12, 2024
In vitro evaluation of using ceftazidime/avibactam against carbapenem-resistant Acinetobacter baumanniiNazanin Pouya, James E Smith, Cole S Hudson, et al.
Computers & Chemical Engineering|January 9, 2025
Rapid Design of Combination Antimicrobial Therapy against <i>Acinetobacter baumannii</i>Brianna M Eales, James Smith, Nazanin Pouya, et al.
Antimicrobial Agents and Chemotherapy|September 22, 2025
Pharmacokinetics of sulbactam-durlobactam in patients with <i>Acinetobacter baumannii</i> ventriculitis: a report of two casesNazanin Pouya, Natalie A Finch, Alejandro Granillo, et al.
Pharmacotherapy|December 4, 2024
Pharmacokinetics of cefiderocol in a patient with carbapenem-resistant Acinetobacter baumannii ventriculitis: A case reportNatalie A Finch, Alejandro Granillo, Nazanin Pouya, et al.
International Journal of Antimicrobial Agents|May 9, 2024
Alternative iron-depleted media for cefiderocol susceptibility testingBrianna M Eales, James E Smith, Nazanin Pouya, et al.
Diagnostic Microbiology and Infectious Disease|July 12, 2025
Impact of iron limitation on in vitro and in vivo activity of ceftazidime against A. baumanniiBrianna M Eales, James E Smith, Nazanin Pouya, et al.
Antimicrobial Agents and Chemotherapy|July 8, 2025
Drug development studies supporting zileuton as a parenteral adjuvant to attenuate antibiotic-associated nephrotoxicityCole S Hudson, James E Smith, Linh T Vuong, et al.
The Journal of Infectious Diseases|May 15, 2026
Genomic and Clinical Features Associated with Reduced Susceptibility to Cefiderocol and Cross-resistance to β-lactam/β-lactamase Inhibitors in a Global Cohort of Pseudomonas aeruginosaStephanie L Egge, Donghoon Kang, Nazanin Pouya, et al.
Pageof 1